Recently in Anaphylaxis Category

FDA Warns On Genentech's Asthma Drug Xolair

|
xolairWASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration warned Wednesday a Genentech Inc. (DNA) asthma drug can cause a life-threatening allergic reaction known as anaphylaxis.

The agency said it's asked the company to put a black-box warning label on the drug, which is sold under the brand name Xolair. A black box warning is the FDA's strongest warning.

Xolair was approved in 2003 to treat adults and adolescents with moderate to severe persistent asthma related to allergies whose symptoms are inadequately controlled with inhaled steroids.

A company spokesman couldn't immediately be reached.

Genentech shares recently rose 8 cents to $87.02.

Copyright (c) 2007 Dow Jones & Company, Inc.

Labor backs allergy training plan

|

LIFE saving allergy training would be mandatory for teachers and childcare workers if Labor wins next month's Victorian election.

Premier Steve Bracks today announced the Government would spend $2.1 million over five years to train childcare workers and teachers how to treat children with life-threatening anaphylaxis - a severe allergic reaction.

The package would include training to reduce the risk of exposure to anaphylactic triggers - such as peanuts and shellfish - and how to administer a life-saving shot of adrenaline through an Epi-pen.